Systemic Lupus Erythematosus: A 2019 Review of Key Advances in Diagnosis, Pathogenesis, and Treatment
Systemic lupus erythematosus (SLE)—a chronic autoimmune disease that can affect nearly any organ—has long baffled clinicians with its extreme variability. But 2019 marked a turning point: updated guidelines, groundbreaking insights into why SLE develops, and new hope for treatments. Yong Fan, Yan-Jie Hao, and Zhuo-Li Zhang from the Department of Rheumatology and Clinical Immunology at Peking University First Hospital synthesized the year’s top research to highlight progress and unmet needs. Here’s what you need to know.
1. New Guidelines: Simplifying Diagnosis and Treatment
For decades, SLE diagnosis relied on a list of symptoms (like rash, joint pain, or kidney issues) and blood tests. In 2019, the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR) launched a score-based system to make diagnosis more consistent.
Key Changes to Classification:
- ANA first: You must test positive for antinuclear antibodies (ANA)—a hallmark of SLE—to even start scoring.
- 10 domains: Points are assigned for clinical symptoms (e.g., kidney disease = 4 points, rash = 2 points) and immune markers (e.g., anti-dsDNA antibodies = 6 points). A total of 10+ points confirms SLE.
This system helps reduce misdiagnosis, especially for people with mild or unusual symptoms. But it also means ANA-negative SLE—a rare subset—can’t be classified using these criteria, highlighting the need for better ANA testing standards.
Treatment Recommendations:
The 2019 update emphasized a treat-to-target approach: aim for remission (no active disease) or low disease activity (mild symptoms) to prevent organ damage and improve quality of life. Key updates:
- Belimumab: The first biologic drug for SLE (approved in China in 2019) is now recommended for people with extra-renal SLE (e.g., skin, joint issues) who don’t respond to first-line therapies (like steroids or hydroxychloroquine).
- Hydroxychloroquine (HCQ): The “cornerstone” of SLE treatment now has a lower recommended dose (≤5 mg/kg daily) to reduce eye damage risk. But researchers are still debating if this lower dose works as well as the previous 6.5 mg/kg.
- Screening: Eye exams for HCQ-related retinopathy start at 5 years of use and continue annually.
2. Pathogenesis: Why Does SLE Happen?
SLE arises when the immune system mistakenly attacks the body’s own cells. 2019 studies uncovered new pieces of this puzzle:
Mitochondrial DNA (mtDNA) as an “Alarm Signal”
Mitochondria—our cells’ “power plants”—release short DNA fragments when stressed (e.g., from inflammation). These fragments slip into the cell’s cytoplasm (via protein pores) and trigger the immune system to make type I interferons—proteins that drive SLE inflammation. Blocking this pathway could quiet the overactive immune response.
A New T Cell Subset Fuels Autoantibodies
Scientists identified a rare T cell type—CXCR5⁻CXCR3⁺PD1hi CD4⁺ T peripheral helper cells—that’s overactive in SLE. These cells “help” B cells make autoantibodies (proteins that attack the body), worsening symptoms. Targeting these T cells could reduce harmful antibody production.
Circular RNAs (circRNAs) as Immune Regulators
CircRNAs—loop-shaped RNA molecules—act like “brakes” on the immune system. SLE patients have fewer circRNAs, which means more activation of a protein (PKR) that drives inflammation. Restoring circRNAs might calm the immune system.
Drug-Induced Lupus and Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs)—used to treat cancer—can trigger SLE in rare cases. A 2019 analysis of FDA data found 18 lupus cases linked to ICIs, highlighting the need to monitor cancer patients for autoimmune side effects.
3. Clinical Manifestations: What SLE Looks Like in Patients
SLE can affect any organ—here’s what 2019 research taught us about common and tricky symptoms:
Lupus Nephritis (LN): Kidney Damage
Up to 50% of SLE patients develop LN, which can lead to chronic kidney disease (CKD) or end-stage renal disease (ESRD). A French study found:
- 10% of LN patients without CKD at diagnosis developed CKD over time.
- 33% of those with CKD progressed to ESRD.
Good news: Kidney transplantation improves survival for LN-ESRD patients, mainly by reducing heart disease and infection risks.
Cutting-edge research used single-cell RNA sequencing to map immune cells in LN kidneys. Urine samples mirrored kidney immune activity—meaning future tests might replace invasive biopsies.
Neuropsychiatric SLE (NP-SLE): Brain and Nerve Issues
NP-SLE causes symptoms from mild brain fog to seizures or psychosis. Diagnosing it is tough—especially distinguishing it from CNS infections (common in SLE patients on immunosuppressants).
A Peking Union Medical College Hospital study created a scoring system to help: 8 factors (e.g., fever, low white blood cell count, abnormal CSF) can predict CNS infection with 85% sensitivity and 84% specificity. If you hit 4+ criteria, infection is more likely.
Autoantibodies (e.g., anti-myelin oligodendrocyte glycoprotein) are also emerging as NP-SLE biomarkers—but no “gold standard” test exists yet.
Musculoskeletal Symptoms: Joint Pain Beyond Arthritis
Arthralgia (joint pain) or synovitis (joint inflammation) affects most SLE patients. Ultrasound revealed that 27% of patients with no clinical arthritis have subclinical inflammation (swelling/tenderness only seen on scans). This “hidden” inflammation correlates with worse symptoms and blood test abnormalities—meaning ultrasound could help guide treatment better than physical exams alone.
4. Prognosis: Why SLE Still Takes a Toll
While 10-year survival has jumped from 63% (1950s) to 95% (today), SLE patients are 3x more likely to die early than people without lupus—especially those under 40. Racial disparities are stark: Black patients have a 3.3x higher mortality risk vs. White patients (2.4x).
Comorbidities (e.g., heart disease, diabetes) explain 27% of this mortality gap. SLE patients are more likely to develop these conditions at diagnosis and over time—underscoring the need for regular screenings.
5. Treatment Advances: New Hope for Patients
2019 was a banner year for SLE therapies—here are the top contenders:
Belimumab: Long-Term Data
A 13-year study confirmed belimumab is safe and effective. Patients on belimumab had:
- Fewer flare-ups.
- 61% lower risk of organ damage vs. standard therapy.
Anifrolumab: Blocking the Interferon Pathway
Anifrolumab (a monoclonal antibody that targets type I interferon receptors) showed promise in a Phase III trial: 47% of patients on anifrolumab had a clinical response at 52 weeks vs. 31% on placebo. It’s now under FDA review.
JAK Inhibitors: Targeting Intracellular Signaling
JAK proteins help transmit immune signals. Two drugs—baricitinib (JAK1/2 inhibitor) and tofacitinib (JAK1/3 inhibitor)—reduced joint pain, skin rash, and steroid use in small trials. JAK inhibitors are already used for rheumatoid arthritis—could they work for SLE?
Low-Dose IL-2: Balancing the Immune System
SLE patients have too many “effector” T cells (which attack the body) and too few “regulatory” T cells (which calm the immune system). Low-dose interleukin-2 (IL-2) boosts regulatory T cells. A Peking University trial found 60% of patients on low-dose IL-2 had a clinical response vs. 33% on placebo—with no extra side effects.
Telitacicept: A Dual B Cell Inhibitor
Telitacicept (developed in China) blocks two proteins that fuel B cell activation (BAFF and APRIL). A Phase II/III trial found 79% of patients on telitacicept had a response at 48 weeks vs. 32% on placebo—making it a top candidate for future approval.
6. What’s Next?
2019 laid the groundwork for better SLE care:
- More precise diagnosis with the EULAR/ACR criteria.
- Deeper understanding of why SLE develops.
- New therapies targeting interferon, B cells, and T cells.
But challenges remain: closing the mortality gap, improving NP-SLE diagnosis, and refining treatment for diverse patient groups. The good news? The pipeline is full—soon, SLE patients could have as many treatment options as those with rheumatoid arthritis.
Final Thoughts
SLE is complex, but 2019 proved we’re moving in the right direction. From guidelines that make diagnosis easier to drugs that target root causes, the year’s progress gives hope to the 5 million people living with lupus worldwide. As research continues, the “butterfly disease” (named for its classic rash) may finally be tamed.
doi: 10.1097/CM9.0000000000000983
Was this helpful?
0 / 0